RxDoctor Payments Data

Sergio Soto, MD

Cardiovascular Disease · Prescott Valley, AZNPI 1942204854

Payments from drug & device makers

$913in general payments, 2019–2025

Across 34 payments — averaging $26.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$290
  • Abbott$155
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$123
  • Abiomed$91
  • E.r. Squibb & Sons, L.L.C.$81
  • Edwards Lifesciences$60
  • plus $114 from 5 others

What the payments were for

  • Food & beverage$913100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$913 in reported general payments places this provider in the 30th percentile of 423 cardiovascular disease providers in Arizona.

See all cardiovascular disease providers in Arizona

Medicare billing

Part B allowed, 2024
$181,835
Medicare patients
921
Services billed
2,271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban562$761,246
Repatha SureclickEvolocumab169$189,885
XareltoRivaroxaban84$131,794
EntrestoSacubitril/Valsartan41$60,750
JardianceEmpagliflozin28$37,182
NexletolBempedoic Acid45$36,517
VascepaIcosapent Ethyl37$34,294
MultaqDronedarone Hcl12$23,177
Praluent PenAlirocumab17$20,145
Atorvastatin Calcium1,568$15,869
Repatha SyringeEvolocumab15$15,471
Ezetimibe595$11,932
Rosuvastatin Calcium476$7,100
Losartan Potassium657$6,968
Dabigatran EtexilateDabigatran Etexilate Mesylate22$5,862

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$761,246562 claims
Johnson & JohnsonXarelto$41$131,79484 claims
NovartisEntresto$14$60,75041 claims
Sanofi-aventis U.S. LLCMultaq$27$23,17712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 423 cardiovascular disease providers in Arizona.

Other cardiovascular disease in Prescott Valley

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →